NCT06300463 2026-04-01
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
Weill Medical College of Cornell University
Phase 2 Recruiting
Clinical Trials
12 trialsNCT05845450 2026-03-12
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Gruppo Oncologico del Nord-Ovest
Phase 2 Recruiting
NCT07227636 2026-02-06
A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04028063 2026-01-27
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
University of Colorado, Denver
Phase 2 Recruiting
NCT06589440 2026-01-15
Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Stingray Therapeutics
Phase 2 Recruiting
NCT06251973 2025-12-02
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06843434 2025-12-02
A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05864534 2025-10-03
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Northwestern University
Phase 2 Recruiting
NCT06843551 2025-08-14
EMPIRE
University of Miami
Phase 2 Recruiting
NCT06780787 2025-06-26
FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery
City of Hope Medical Center
Phase 2 Recruiting
NCT05891821 2025-05-08
Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)
Immune Oncology Research Institute
Phase 2 Recruiting
NCT06322108 2025-05-08
Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)
Immune Oncology Research Institute
Phase 2 Recruiting